MedKoo product information:

 Flutamide

flutamide is a toluidine derivative and nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

DRUG DESCRIPTION

EULEXIN Capsules contain flutamide, an acetanilid, nonsteroidal, orally active anti-androgen having the chemical name, 2-methyl-N-[4-nitro-3 (trifluoromethyl) phenyl] propanamide. Each capsule contains 125 mg flutamide. The compound is a buff to yellow powder with a molecular weight of 276.2. The inactive ingredients for EULEXIN Capsules include: corn starch, lactose, magnesium stearate, povidone, and sodium lauryl sulfate. Gelatin capsule shells may contain methylparaben, propylparaben, butylparaben, and the following dye systems: FD&C Blue 1, FD&C Yellow 6, and either FD&C Red 3 or FD&C Red 40 plus D&C Yellow 10, with titanium dioxide and other inactive ingredients.

Use in prostate cancer

Gonadotropin-releasing hormone (GnRH) is released by the hypothalamus in a pulsatile fashion; this causes the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates the testes to produce testosterone, which is metabolized to DHT by the enzyme 5α-reductase. DHT, and to a much smaller extent, testosterone, stimulate prostate cancer cells to grow. Therefore, blocking these androgens can provide powerful treatment for prostate cancer, especially metastatic disease. Normally administered are analogues of GnRH, such as leuprolide or goserelin. Although they stimulate the same receptors that GnRH does, since they are present continuously and not in a pulsatile manner, they serve to inhibit the pituitary and therefore block the whole chain. However, they initially cause a surge in activity; this is not solely a theoretical risk but may cause the cancer to flare. Flutamide was initially used at the beginning of GnRH-analogue therapy to block this surge, and it and other nonsteroidal anti-androgens continue in this use. There have been studies to investigate the benefit of adding an anti-androgen to surgical orchiectomy or its continued use with a GnRH analogue (combined androgen blockade, CAB). Adding anti-androgens to orchiectomy showed no benefit, while a small benefit was shown with adding anti-androgens to GnRH analogues

Unfortunately, therapies which lower testosterone levels, such as orchiectomy or GnRH-analogue administration, also have significant side effects. Compared to these therapies, treatment with antiandrogens exhibits "fewer hot flashes, less of an effect on libido, less muscle wasting, fewer personality changes, and less bone loss." However, antiandrogen therapy alone is less effective than surgery. Nevertheless, given the advanced age of many with prostate cancer, as well as other features, many men may choose antiandrogen therapy alone for a better quality of life. From: http://en.wikipedia.org/wiki/Flutamide.

 1: Ingram JR, Grindlay DJ, Williams HC. Management of acne vulgaris: an evidence-based update. Clin Exp Dermatol. 2010 Jun;35(4):351-4. Epub 2009 Oct 23. PubMed PMID: 19874358.

2: Yee DS, Lowrance WT, Eastham JA, Maschino AC, Cronin AM, Rabbani F. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int. 2010 Jan;105(2):185-90. Epub 2009 Jul 8. PubMed PMID: 19594741; PubMed Central PMCID: PMC2807908.

3: Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009 Aug;104(3):310-4. Epub 2009 Feb 23. PubMed PMID: 19239458.

4: Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst. 2009 Feb 18;101(4):228-36. Epub 2009 Feb 10. PubMed PMID: 19211454; PubMed Central PMCID: PMC2734115.

5: Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. Review. PubMed PMID: 18471790.

6: Albrecht W. Editorial comment on: continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol. 2008 Aug;54(2):390-1. Epub 2008 Mar 6. PubMed PMID: 18339476.

7: D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW; Cancer and Leukemia Group B. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May;71(5):933-7. Epub 2008 Feb 21. PubMed PMID: 18291508.

8: Pathak S, Singh R, Verschoyle RD, Greaves P, Farmer PB, Steward WP, Mellon JK, Gescher AJ, Sharma RA. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer Lett. 2008 Mar 8;261(1):74-83. Epub 2007 Dec 21. PubMed PMID: 18096312.

9: Chodak G, Gomella L, Phung de H. Combined androgen blockade in advanced prostate cancer: looking back to move forward. Clin Genitourin Cancer. 2007 Sep;5(6):371-8. Review. PubMed PMID: 17956709.

10: Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED; Southwest Oncology Group. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol. 2007 Nov;178(5):1946-51; discussion 1951. Epub 2007 Sep 17. PubMed PMID: 17868721.

11: Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J; Genitourinary Cancer Disease Site Group; Cancer Care Ontario Program in Evidence-based Care. Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol. 2006 Jun;13(3):81-93. PubMed PMID: 17576447; PubMed Central PMCID: PMC1891181.

12: Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006 Dec 1;107(11):2597-603. PubMed PMID: 17039498.

13: Brawer MK, Crawford ED, Labrie F, Mendoza-Valdes A, Miller PD, Petrylak DP. Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol. 2001;3 Suppl 2:S59-68. PubMed PMID: 16986000; PubMed Central PMCID: PMC1476080.

14: Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006 Oct;91(10):3970-80. Epub 2006 Jul 25. PubMed PMID: 16868063.

15: Daskivich TJ, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol. 2006 May;16(3):173-8. Review. PubMed PMID: 16679855.

16: Klotz L. Combined androgen blockade: an update. Urol Clin North Am. 2006 May;33(2):161-6, v-vi. Review. PubMed PMID: 16631454.

17: Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs. 2005 Nov-Dec;28(6):481-6. Review. PubMed PMID: 16330971.

18: Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer. 2006 Jan 1;106(1):51-7. PubMed PMID: 16323171.

19: Akaza H, Chodak GW, Hirao Y. [Usefulness and positioning of MAB therapy for prostate cancer]. Gan To Kagaku Ryoho. 2005 Oct;32(10):1507-20. Review. Japanese. PubMed PMID: 16227758.

20: Ma G, Troxel AB, Heitjan DF. An index of local sensitivity to nonignorable drop-out in longitudinal modelling. Stat Med. 2005 Jul 30;24(14):2129-50. PubMed PMID: 15909292.

21: Klotz L, Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer. 2005 Mar;3(4):215-9. Review. PubMed PMID: 15882477.

22: Miyakita H. [Hormonal therapy for prostatic cancer--state of the art]. Nippon Rinsho. 2005 Feb;63(2):305-8. Review. Japanese. PubMed PMID: 15714983.

23: Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab. 2005 Feb;90(2):657-60. Epub 2004 Nov 23. PubMed PMID: 15562007.

24: Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N. Monotherapy in advanced prostate cancer: an overview. Exp Oncol. 2004 Sep;26(3):185-91. Review. PubMed PMID: 15494685.

25: Moul JW, Chodak G. Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S2-7. Review. PubMed PMID: 15365575.

26: Rocco B, Matei DV, de Cobelli O, Rocco F. Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70. Eur Urol. 2004 Aug;46(2):272-3; author reply 273. PubMed PMID: 15245825.

27: Ryan CJ, Small EJ. The selection of hormonal therapy in prostate cancer: who, when, and for how long? J Natl Compr Canc Netw. 2004 May;2(3):261-8. Review. PubMed PMID: 19795609.

28: Schellhammer PF, Davis JW. An evaluation of bicalutamide in the treatment of prostate cancer. Clin Prostate Cancer. 2004 Mar;2(4):213-9. Review. PubMed PMID: 15072604.

29: Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int. 2004;72(2):91-8. Review. PubMed PMID: 14963347.

30: Labrie F, Cusan L, Gomez JL, Candas B, Bélanger A, Luu-The V, Labrie C, Simard J. [From the gene to the clinic: prostate cancer death can now be an exception?]. Med Sci (Paris). 2003 Oct;19(10):910-9. Review. French. PubMed PMID: 14612999.

31: Jani AB, Basu A, Abdalla I, Connell PP, Krauz L, Vijayakumar S. Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer. Am J Clin Oncol. 2003 Aug;26(4):382-5. PubMed PMID: 12902891.

32: Oh WK. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol. 2003 May-Jun;21(3):229-34. Review. PubMed PMID: 12810211.

33: Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate. 2003 May 15;55(3):168-79. PubMed PMID: 12692782.

34: Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int. 2003 Mar;91(5):455-61. Review. PubMed PMID: 12603397.

35: Namiki M, Mizokami A. [Total androgen blockade]. Nippon Rinsho. 2002 Dec;60 Suppl 11:193-8. Review. Japanese. PubMed PMID: 12599570.

36: Maeda O, Usami M. [Antiandrogen in prostate cancer]. Nippon Rinsho. 2002 Dec;60 Suppl 11:188-92. Review. Japanese. PubMed PMID: 12599569.

37: Sakai H, Kanetake H. [First line therapy in the treatment of metastatic prostate cancer]. Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Review. Japanese. PubMed PMID: 12557704.

38: Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis. 2001;4(4):196-203. PubMed PMID: 12497018.

39: Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis. 1999 Jan;2(1):4-8. PubMed PMID: 12496859.

40: Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan;169(1):245-50. PubMed PMID: 12478146.

41: Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003 Jan;169(1):164-9. PubMed PMID: 12478127.

42: Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002 Sep;168(3):1008-12. PubMed PMID: 12187210.

43: Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA; Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc. 2002 Jun;77(6):561-71. Review. PubMed PMID: 12059127.

44: Stav SY, Segal G. [The role of bicalutamide in the treatment of prostate cancer]. Harefuah. 2002 Apr;141(4):379-83, 408, 407. Review. Hebrew. PubMed PMID: 12017896.

45: D'Amico A. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology. 2001 Aug;58(2 Suppl 1):78-82. PubMed PMID: 11502455.

46: Collette L, Studer UE, Schröder FH, Denis LJ, Sylvester RJ. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate. 2001 Jun 15;48(1):29-39. PubMed PMID: 11391684.

47: Noël G, Mazeron JJ. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials]. Cancer Radiother. 2001 Apr;5(2):205. French. PubMed PMID: 11355590.

48: Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, Bennett CL. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001 Apr;57(4):727-32. PubMed PMID: 11306391.

49: Alberts SR, Blute ML. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urology. 2001 Apr;57(4 Suppl 1):188-90. PubMed PMID: 11295624.

50: Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001 Feb 7;93(3):219-25. PubMed PMID: 11158191.

51: Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review. PubMed PMID: 11098244.

52: Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf. 2000 Nov;23(5):381-90. Review. PubMed PMID: 11085345.

53: Debruyne FM, Witjes WP. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol Urol. 2000 Fall;4(3):251-6;discussion 257. PubMed PMID: 11062381.

54: Fair WR, Betancourt JE. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol. 2000 Fall;4(3):241-8;discussion 249-50. PubMed PMID: 11062380.

55: Klotz L, Gleave M, Goldenberg SL. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol. 2000 Fall;4(3):233-7;discussion 239. Review. PubMed PMID: 11062379.

56: Roach M 3RD, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):617-27. Erratum in: Int J Radiat Oncol Biol Phys 2000 Aug 1;48(1):313. Mohuidden M [corrected to Mohiuddin M]. PubMed PMID: 10837944.

57: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000 Apr 29;355(9214):1491-8. PubMed PMID: 10801170.

58: Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, Turner S, Spry N, Poulsen M, North J, Kovacev O, Denham J. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01). Australas Radiol. 2000 Feb;44(1):65-71. PubMed PMID: 10761262.

59: Altwein JE, Mohandessi B. [Maximal androgen blockade]. Urologe A. 2000 Jan;39(1):27-35. Review. German. PubMed PMID: 10663193.

60: Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol. 2000 Jan-Feb;18(1):52-74. Review. PubMed PMID: 10617897.

61: Murphy GP. Review of phase II hormone refractory prostate cancer trials. Urology. 1999 Dec;54(6A Suppl):19-21. Review. PubMed PMID: 10606280.

62: Akaza H. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects]. Gan To Kagaku Ryoho. 1999 Jul;26(8):1201-7. Japanese. PubMed PMID: 10431591.

63: Tyrrell CJ. Controversies in the management of advanced prostate cancer. Br J Cancer. 1999 Jan;79(1):146-55. PubMed PMID: 10408706; PubMed Central PMCID: PMC2362166.

64: Kolvenbag GJ, Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate. 1999 Apr 1;39(1):47-53. Review. PubMed PMID: 10221266.

65: Albertsen PC. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1999 Apr 7;91(7):646. PubMed PMID: 10203286.

66: Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol. 1999;35 Suppl 1:23-5; discussion 26. PubMed PMID: 10081699.

67: Wasan HS. Effect of flutamide on survival in patients with pancreatic cancer. No recommendations can be made. BMJ. 1999 Jan 30;318(7179):327-8. PubMed PMID: 10075464.

68: Rosendahl I, Kiebert GM, Curran D, Cole BF, Weeks JC, Denis LJ, Hall RR. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer. Prostate. 1999 Feb 1;38(2):100-9. PubMed PMID: 9973095.

69: Studer UE, Mills RD. Arguments against the long-term use of combined androgen blockade. Eur Urol. 1998;34 Suppl 3:29-32. Review. PubMed PMID: 9854193.

70: Wajsman Z. Arguments for the long-term use of combined androgen blockade. Eur Urol. 1998;34 Suppl 3:25-8. Review. PubMed PMID: 9854192.

71: Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol. 1998;34 Suppl 3:18-23. Review. PubMed PMID: 9854191.

72: Denis L. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. Urology. 1998 May;51(5A Suppl):50-7. PubMed PMID: 9610558.

73: Goa KL, Spencer CM. Bicalutamide in advanced prostate cancer. A review. Drugs Aging. 1998 May;12(5):401-22. Review. Erratum in: Drugs Aging 1998 Jul;13(1):41. PubMed PMID: 9606617.

74: Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet. 1998 May;34(5):405-17. Review. PubMed PMID: 9592622.

75: Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res. 1998 Jan;4(1):37-44. PubMed PMID: 9516950.

76: Bono AV, DiSilverio F, Robustelli della Cuna G, Benvenuti C, Brausi M, Ferrari P, Gibba A, Galli L. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group. Urol Int. 1998;60 Suppl 1:18-24. PubMed PMID: 9563140.

77: Boccon-Gibod L. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur Urol. 1998;33(2):159-64. Review. PubMed PMID: 9519357.

78: Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol. 1998;33(2):134-43. PubMed PMID: 9519354.

79: Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate. 1998 Jan 1;34(1):61-72. Review. PubMed PMID: 9428389.

80: Okada K, Hachiya T. [Significance of neoadjuvant therapy for prostate cancer]. Nippon Hinyokika Gakkai Zasshi. 1997 Sep;88(9):769-77. Review. Japanese. PubMed PMID: 9364842.

81: Wehbe TW, Stein BS, Akerley WL. Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin Proc. 1997 Oct;72(10):932-4. PubMed PMID: 9379696.

82: Smith A, Harbour D, Liebmann J. Acute renal failure in a patient receiving treatment with suramin. Am J Clin Oncol. 1997 Aug;20(4):433-4. PubMed PMID: 9256906.

83: Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Cancer. 1997 May 15;79(10):1964-8. PubMed PMID: 9149024.

84: McLeod DG, Johnson CF, Klein E, Peabody JO, Coffield S, Soloway M. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. Urology. 1997 Mar;49(3A Suppl):70-3. PubMed PMID: 9123740.

85: Goethuys H, Baert L, Van Poppel H, Lieskovsky G, Brady LW, Petrovich Z. Treatment of metastatic carcinoma of the prostate. Am J Clin Oncol. 1997 Feb;20(1):40-5. Review. PubMed PMID: 9020286.

86: Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997 Jan 15;89(2):158-65. PubMed PMID: 8998185.

87: Trachtenberg J. Progress in complete androgen blockade. Eur Urol. 1997;31 Suppl 2:8-10; discussion 24-7. PubMed PMID: 9074904.

88: Dacker R. Chemotherapy and prostate cancer. Radiol Technol. 1997 Jan-Feb;68(3):194-5. PubMed PMID: 9008013.

89: Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother. 1997 Jan;31(1):65-75. Review. PubMed PMID: 8997470.

90: Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 Jan;15(1):382-8. Review. PubMed PMID: 8996165.

91: Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. Cancer and Leukemia Group B trials for advanced prostate cancer. Semin Oncol. 1996 Dec;23(6 Suppl 14):28-31. Review. PubMed PMID: 8996582.

92: Zerbib M, Payan C. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 1996 Oct;48(4):661-3. PubMed PMID: 8886082.

93: Scalliet P. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy. Acta Urol Belg. 1996 May;64(2):63-4. PubMed PMID: 8701815.

94: Boccon-Gibod L. Maximum androgen blockade in 1996. Eur Urol. 1996;30 Suppl 1:15-8; discussion 19-21. Review. PubMed PMID: 8977985.

95: Blackledge G, Kolvenbag G, Nash A. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Anticancer Drugs. 1996 Jan;7(1):27-34. Review. PubMed PMID: 8742095.

96: Blackledge GR. Clinical progress with a new antiandrogen, Casodex (bicalutamide). Eur Urol. 1996;29 Suppl 2:96-104. Review. PubMed PMID: 8717470.

97: Crawford ED. Combined androgen blockade. Eur Urol. 1996;29 Suppl 2:54-61. Review. PubMed PMID: 8717465.

98: da Silva FC, Fossa SD, Aaronson NK, Serbouti S, Denis L, Casselman J, Whelan P, Hetherington J, Fava C, Richards B, Robinson MR. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer. 1996 Jan;32A(1):72-7. PubMed PMID: 8695246.

99: Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology. 1996 Jan;47(1A Suppl):70-9; discussion 80-4. Review. PubMed PMID: 8560681.

100: Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology. 1996 Jan;47(1A Suppl):61-9. Review. PubMed PMID: 8560680.

101: Blackledge GR. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology. 1996 Jan;47(1A Suppl):44-7; discussion 48-53. PubMed PMID: 8560678.

102: Klein EA. Hormone therapy for prostate cancer: a topical perspective. Urology. 1996 Jan;47(1A Suppl):3-12; discussion 29-32. Review. PubMed PMID: 8560675.

103: Randal J. Survey shows M.D.s' ambivalence about maximum androgen blockade. J Natl Cancer Inst. 1995 Dec 20;87(24):1827-9. PubMed PMID: 7494222.

104: Crawford ED. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 1995 Dec;46(6):899-901. PubMed PMID: 7502440.

105: Denis L. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Prostate. 1995 Nov;27(5):233-40. Review. PubMed PMID: 7479390.

106: DeAntoni E, Crawford ED. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. Urologe A. 1995 Sep;34(5):382-8. Review. German. PubMed PMID: 7483154.

107: Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995 Aug;46(2):142-8. Review. PubMed PMID: 7624983.

108: Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995 Aug;154(2 Pt 1):424-8. PubMed PMID: 7541859.

109: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet. 1995 Jul 29;346(8970):265-9. PubMed PMID: 7630245.

110: Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Jul;7(1):49-74. Review. PubMed PMID: 7579781.

111: Soloway MS. Role of induction androgen deprivation before radical prostatectomy. Semin Urol. 1995 May;13(2):142-7. Review. PubMed PMID: 7638472.

112: Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol. 1995 May;153(5):1575-9. PubMed PMID: 7536270.

113: Crawford ED, Hussain M, DeAntoni EP, Thompson IM, Eisenberger MA, Blumenstein B, Coltman CA Jr. Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol. 1995 Jan-Feb;11(1):60-4. Review. PubMed PMID: 7754277.

114: Kehinde EO, Terry TR, Mistry N, Horsburgh T, Sandhu DP, Bell PR. UK studies on suramin therapy in hormone resistant prostate cancer. Cancer Surv. 1995;23:217-29. PubMed PMID: 7621460.

115: van der Vange N, Greggi S, Burger CW, Kenemans P, Vermorken JB. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol. 1995;34(6):813-20. PubMed PMID: 7576750.

116: Cheson BD, Kaplan RS, Phillips PH. Clinical trials referral resource. Prostate cancer. Oncology (Williston Park). 1994 Dec;8(12):35-6. PubMed PMID: 7534101.

117: Narayan P, Lowe BA, Carroll PR, Thompson IM. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br J Urol. 1994 May;73(5):544-8. PubMed PMID: 8012777.

118: Takahashi S, Hasegawa F, Isurugi K. [Application of antiandrogens on prostatic diseases]. Nippon Rinsho. 1994 Mar;52(3):809-14. Review. Japanese. PubMed PMID: 7513031.

119: Denis L. Role of maximal androgen blockade in advanced prostate cancer. Prostate Suppl. 1994;5:17-22. PubMed PMID: 8172710.

120: Suciu S, Sylvester R, Iversen P, Christensen I, Denis L. Comparability of prostate trials. Cancer. 1993 Dec 15;72(12 Suppl):3841-6. Review. PubMed PMID: 8252500.

121: da Silva FC. Quality of life in prostatic cancer patients. Cancer. 1993 Dec 15;72(12 Suppl):3803-6. PubMed PMID: 8252494.

122: Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer. 1993 Dec 1;72(11):3156-73. Review. PubMed PMID: 7694785.

123: Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993 Aug;11(8):1566-72. PubMed PMID: 7687666.

124: Witeska A, Owczarczyk B, Dutkiewicz S, Tałałaj M. [Attempt at using chemoluminescence in modern diagnosis and monitoring of therapy in prostatic cancer]. Wiad Lek. 1993 Jul;46(13-14):502-5. Polish. PubMed PMID: 8030327.

125: Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993 Apr;11(4):607-15. PubMed PMID: 7683043.

126: Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993 Mar;149(3):607-9. PubMed PMID: 7679759.

127: da Silva FC, Reis E, Costa T, Denis L. Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer. 1993 Feb 1;71(3 Suppl):1138-42. PubMed PMID: 8428336.

128: Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer. 1993 Feb 1;71(3 Suppl):1083-8. Review. PubMed PMID: 8428332.

129: McLeod DG. Antiandrogenic drugs. Cancer. 1993 Feb 1;71(3 Suppl):1046-9. Review. PubMed PMID: 8428326.

130: Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol. 1993;24 Suppl 2:106-12. PubMed PMID: 7505229.

131: Van Poppel H, Ameye F, Oyen R, Van De Voorde W, Baert L. Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy. Acta Urol Belg. 1992;60(3):73-82. PubMed PMID: 1492636.

132: Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991 Nov-Dec;1(6):487-509. Review. PubMed PMID: 1794035.

133: Huben RP, Perrapato SD. Drug therapy of prostatic cancer. Drugs Aging. 1991 Sep-Oct;1(5):353-63. Review. PubMed PMID: 1838950.

134: Chime-Udeh E. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2). Conn Med. 1991 Sep;55(9):526-8. Review. PubMed PMID: 1748007.

135: Brogden RN, Chrisp P. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging. 1991 Mar;1(2):104-15. Review. PubMed PMID: 1794008.

136: Crawford ED, Nabors WL. Total androgen ablation: American experience. Urol Clin North Am. 1991 Feb;18(1):55-63. PubMed PMID: 1899495.

137: Denis L, Smith P, Carneiro de Moura JL, Newling D, Bono A, Keuppens F, Mahler C, Robinson M, Sylvester R, De Pauw M, et al. Total androgen ablation: European experience. The EORTC GU Group. Urol Clin North Am. 1991 Feb;18(1):65-73. PubMed PMID: 1825144.

138: Gaillard-Moguilewsky M. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology. 1991;37(2 Suppl):5-12. Review. PubMed PMID: 1992602.

139: Guidez C. [How can a nursing team participate in a clinical trial? Zoladex, flutamide trial]. Soins. 1990 Sep;(540):53. French. PubMed PMID: 2151069.

140: Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer. 1990 Sep 1;66(5 Suppl):1067-73. PubMed PMID: 2144208.

141: Iversen P, Christensen MG, Friis E, Hornbøl P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 1990 Sep 1;66(5 Suppl):1058-66. PubMed PMID: 2144207.

142: Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, Sylvester R, De Pauw M, Vermeylen K, Ongena P. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group. Cancer. 1990 Sep 1;66(5 Suppl):1045-57. PubMed PMID: 2144206.

143: Suciu S, Sylvester R, Iversen P, Christensen I, Denis L. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer. Cancer. 1990 Sep 1;66(5 Suppl):1029-34. PubMed PMID: 2144205.

144: Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, Sylvester R, Armitage TG. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer. 1990 Sep 1;66(5 Suppl):1009-16. PubMed PMID: 2144203.

145: Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990 Sep 1;66(5 Suppl):1039-44. PubMed PMID: 2118417.

146: Denis L, Keuppens F, Robinson M, Mahler C, Smith P, Pinto de Carvalho AP, Newling D, Bono A, Sylvester R, De Pauw M, et al. Complete androgen blockade: data from an EORTC 30853 trial. Semin Urol. 1990 Aug;8(3):166-74. PubMed PMID: 2144656.

147: Crawford ED, Goodman P, Blumenstein B. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo. Semin Urol. 1990 Aug;8(3):154-8. PubMed PMID: 2119048.

148: Balducci L, Parker M, Hescock H, Tantranond P, Sexton W. Systemic management of prostate cancer. Am J Med Sci. 1990 Mar;299(3):185-92. Review. PubMed PMID: 2180297.

149: Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res. 1990;16(7):361-9. PubMed PMID: 2152694.

150: Schröder FH. Antiandrogenic substances in the management of prostatic cancer. Recent Results Cancer Res. 1990;118:163-73. Review. PubMed PMID: 2146723.

151: Di Silverio F, Sciarra F, D'Eramo G. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate. Eur Urol. 1990;18(1):10-5. PubMed PMID: 2144819.

152: Nabors W, Crawford ED. Luteinizing hormone releasing hormone agonists: the US experience. J Int Med Res. 1990;18 Suppl 1:31-4. PubMed PMID: 2108884.

153: Pavone-Macaluso M, Pavone C, Serretta V, Daricello G. Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. Urology. 1989 Oct;34(4 Suppl):27-36; discussion 46-56. Review. PubMed PMID: 2678684.

154: Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24. Erratum in: N Engl J Med 1989 Nov 16;321(20):1420. PubMed PMID: 2503724.

155: Brogden RN, Clissold SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs. 1989 Aug;38(2):185-203. Review. PubMed PMID: 2670515.

156: Flutamide for prostate cancer. Med Lett Drugs Ther. 1989 Jul 28;31(797):72. PubMed PMID: 2501635.

157: Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer. Prog Clin Biol Res. 1989;303:161-7. Review. PubMed PMID: 2674982.

158: Newling DW. The use of flutamide as monotherapy in the treatment of advanced prostate cancer. Prog Clin Biol Res. 1989;303:117-21. Review. PubMed PMID: 2674980.

159: Waxman J. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer. Prog Clin Biol Res. 1989;303:61-8. PubMed PMID: 2528741.

160: Lunglmayr G. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group. Prog Clin Biol Res. 1989;303:145-51. PubMed PMID: 2528737.

161: Carvalho AP, de Moura JL, Denis L, Newling D, Smith P, Bono A, Sylvester R, De Pauw M, Ongena P. Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group. Prog Clin Biol Res. 1989;303:129-43. PubMed PMID: 2528736.

162: Flamm J, Fischer M. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer]. Wien Klin Wochenschr. 1988 Sep 9;100(17):589-92. German. PubMed PMID: 3055689.

163: Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs. 1988 Sep;6(3):207-10. PubMed PMID: 3192386.

164: Geller J, Albert J, Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol. 1988 Apr;15(2 Suppl 1):53-61. Review. PubMed PMID: 3285484.

165: de Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology. 1988 Apr;31(4):312-7. PubMed PMID: 3281365.

166: Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol. 1988 Feb;61(2):140-2. PubMed PMID: 3280080.

167: Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, Monfette G, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J Steroid Biochem. 1988;30(1-6):107-17. PubMed PMID: 3290578.

168: Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Prog Clin Biol Res. 1988;260:41-62. PubMed PMID: 3283766.

169: Da Silva FC, Aaronson N. Quality of life assessment in prostatic cancer. Prog Clin Biol Res. 1988;260:119-21. PubMed PMID: 2966404.

170: Sogani PC, Whitmore WF Jr. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma. Cancer Treat Res. 1988;39:131-45. Review. PubMed PMID: 2908604.

171: Sogani PC, Fair WR. Treatment of advanced prostatic cancer. Urol Clin North Am. 1987 May;14(2):353-71. Review. PubMed PMID: 2953100.

172: Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J Steroid Biochem. 1986 Nov;25(5B):877-83. PubMed PMID: 3100871.

173: Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology. 1984 Nov;24(5 Suppl):30-8. PubMed PMID: 6437034.

174: Mattox DE, Von Hoff DD, McGuire WL. Androgen receptors and antiandrogen therapy for laryngeal carcinoma. Arch Otolaryngol. 1984 Nov;110(11):721-4. PubMed PMID: 6385937.

175: Sogani PC, Vagaiwala MR, Whitmore WF Jr. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer. 1984 Aug 15;54(4):744-50. PubMed PMID: 6378356.

176: deKernion JB, Lindner A. Chemotherapy of hormonally unresponsive prostatic carcinoma. Urol Clin North Am. 1984 May;11(2):319-26. Review. PubMed PMID: 6233779.

177: Sanford EJ, Bowditch RR, Rohner TJ Jr, Bardin CW. Treatment of advanced prostatic cancer with flutamide. Pa Med. 1979 Sep;82(9):29-31. PubMed PMID: 386212.

178: Airhart RA, Barnett TF, Sullivan JW, Levine RL, Schlegel JU. Flutamide therapy for carcinoma of the prostate. South Med J. 1978 Jul;71(7):798-801. PubMed PMID: 78529.

179: Jacobo E, Schmidt JD, Weinstein SH, Flocks RH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology. 1976 Sep;8(3):231-3. PubMed PMID: 788293.

180: Schmidt JD. Chemotherapy of prostatic cancer. Urol Clin North Am. 1975 Feb;2(1):185-96. Review. PubMed PMID: 1093059.